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Abstract
Background: Acquisition of drug-resistance in cancer has led to treatment failure, however, their mechanisms have
not been clarified yet. Recent observations indicated that aberrant expressed microRNA (miRNA) caused by
chromosomal alterations play a critical role in the initiation and progression of cancer. Here, we performed an
integrated genomic analysis combined with array-based comparative hybridization, miRNA, and gene expression
microarray to elucidate the mechanism of drug-resistance.
Results: Through genomic approaches in MCF7-ADR; a drug-resistant breast cancer cell line, our results reflect the
unique features of drug-resistance, including MDR1 overexpression via genomic amplification and miRNA-mediated
TP53INP1 down-regulation. Using a gain of function study with 12 miRNAs whose expressions were down-
regulated and genome regions were deleted, we show that miR-505 is a novel tumor suppressive miRNA and
inhibits cell proliferation by inducing apoptosis. We also find that Akt3, correlate inversely with miR-505, modulates
drug sensitivity in MCF7-ADR.
Conclusion: These findings indicate that various genes and miRNAs orchestrate to temper the drug-resistance in
cancer cells, and thus acquisition of drug-resistance is intricately controlled by genomic status, gene and miRNA
expression changes.
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Background
Systemic therapy improves disease-free survival in patients
with breast cancer, but does not cure patients with
advanced or metastatic disease, and fails to benefit the
majority of patients with localized breast cancer. Intrinsic
resistance to chemotherapy is emerging as a significant
cause of treatment failure, and evolving research has iden-
tified several potential causes of resistance [1]. For
instance, P-glycoprotein (Pgp), the drug efflux pump
encoded by the MDR-1 gene is associated with multidrug
resistance in several kinds of advanced cancer. Further-
more, the multidrug resistance-associated protein MRP1
[2,3], breast cancer resistance protein (ABCG2) and other
transporters [4], which act as energy-dependent efflux
pumps capable of expelling a large range of xenobiotics,
have been reported to be upregulated in tumor cells show-
ing the multidrug-resistant phenotype. In addition, overex-
pression of anti-apoptotic proteins, such as Bcl-2 and
Bcl-xL, are also associated with drug resistance and poor
clinical outcome in cancer patients. It is essential to decide
the molecular target to treat the advanced cancer by mole-
cular targeted therapies such as RNA interference and
antibody treatment, however, regulatory networks under-
lying drug resistance in cancer cells have been elusive.
MicroRNAs (miRNAs) are small non-coding RNA of
21-25nt transcripts, playing central roles in physiological
and pathological processes, including cell differentiation,
apoptosis, and oncogenesis by either inducing mRNA
degradation or by regulating the translational efficiency
of mRNA [5-7]. Recently, several research groups have
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are frequently modulated by genomic aberrations, such
as genomic DNA copy number gain or loss, transloca-
tions, and epigenetic regulations [8]. For example, miR-
15a and miR-16-1, whose genomic regions are deleted
and expressions are down-regulated in the majority of
chronic lymphocytic leukemia (CLL). Furthermore, their
target Bcl-2 is overexpressed in CLL at the mRNA and
protein level [9]. Another study showed that the expres-
sion level of miR-34a was down-regulated by deletion of
1p36 heterozygosity in neuroblastoma and contributed to
an aggressive phenotype [10]. As reported in the studies
of cancer genetics in lung, leukemia, colon, breast and
ovary, a large number of miRNAs are located at chromo-
somal fragile sites, i.e., minimal regions of loss of hetero-
zygosity (LOH) and minimal regions of genomic
amplification [11]. These reports indicated that the
emphasis on a genomic analysis was due to the fact that
DNA copy number alterations are associated with
expression levels of miRNAs and genes.
In this study, to better understand the regulatory net-
work underlying drug resistance in breast cancer cells, we
focus on miRNAs and genes located on the genome-
amplified and -deleted regions because genomic aberration
is closely associated with gene expression, and this expres-
sion alteration might be constantly maintained. For the
identification of molecular targets, we initially performed
an integrated genomic analysis to compare the DNA copy
number and expression profile of mRNA and miRNA
between MCF7; a parental breast cancer cell line and
MCF7-ADR; a drug-resistant breast cancer cell line
[12,13]. Through the genomic analysis, we found that the
genomic alterations of drug resistance-related genes, e.g.
amplified genomic regions and overexpression of MDR-1
and miRNA-mediated TP53INP1 down-regulation. In
addition, of 12 miRNAs whose expressions were down-
regulated and genomic regions were deleted, we deter-
mined that miR-505 promotes the inhibition of cell
growth in MCF7-ADR cells, by inducing apoptotic cell
death in the presence of docetaxel (DOC).
Methods
Cell culture
MCF7 human mammary carcinoma cells and multidrug-
resistant MCF7-ADR human mammary carcinoma cells
were obtained from Shien-Lab, Medical Oncology,
National Cancer Center Hospital. MCF7-ADR-Luc cells
were established by transfecting with a pLuc-neo expres-
sion vector, which has the firefly luciferase GL3 cDNA
cloned into the downstream of the SV40 promoter and
the G418 selective marker gene. Cells were selected in a
medium containing 0.6 mg/ml of G418 (Gibco BRL) and
were maintained and passaged in an RPMI 1640 medium
(Gibco BRL) supplemented with 10% fetal bovine serum
(Gibco BRL) under 5% CO2 in a humidified incubator at
37°C.
RNA and genomic DNA extraction
Total RNA was extracted from MCF7, MCF7-ADR, and
MCF7-ADR-Luc cells using the ISOGEN solution (Nip-
pon Gene, Tokyo, Japan) according to the manufacturer’s
protocol. Genomic DNA was prepared from MCF7 and
MCF7-ADR. The yield and purity of the genomic DNA
and total RNA were measured using a NanoDrop ND-
1000 spectrophotometer (Thermo Fisher Scientific). The
quality of the total RNA was verified to have an RNA
Integrity Number using a Bioanalyzer and RNA 6000 Lab-
Chip Kit (Agilent Technologies).
Oligonucleotide array CGH (aCGH) Analysis
All DNA labeling reactions and hybridizations were
carried out following the manufacture’s protocol (Agilent
Oligonucleotide Array-Based CGH for Genomic DNA
Analysis, Version 4.0, Direct Method). Briefly, 3.0 μgo f
MCF-7, MCF7-ADR and reference DNA (Promega,
female, p/n G1521) were digested with AluIa n dRsaIf o r
2 hours at 37°C, followed by heat inactivation at 65°C for
10 minutes. Digested DNA was then labeled using the
Agilent Genomic DNA Labeling Kit Plus (p/n 5188-5309)
using random primers and the exo-Klenow fragment to
differentially label genomic DNA samples with fluores-
cently labeled nucleotides. All experimental and reference
samples were labeled with Cyanine-5 dUTP and Cyanine-
3 dUTP, separately, for 2 hours at 37°C to enable duplicate
hybridizations with the corresponding dye reversal arrays.
Experimental and reference targets for each hybridization
were purified with a Microcon YM-30 column (Millipore)
and validated by the NanoDrop ND-1000, respectively to
ensure the yield and the specific dye incorporation activity
of the labeled genomic DNA. The individual pair of
labeled targets were combined together, mixed with Cot-1
DNA (Invitrogen) and 10xBlocking Agent (Agilent), and
then mixed with Agilent 2xHybridization Buffer (p/n
5188-5220). Before hybridization, the combined mixtures
were denatured for 3 minutes at 95°C, incubated for
30 minutes at 37°C and then applied to the Agilent
Human 244A CGH arrays (G4411B). Using an Agilent
microarray hybridization chambers, the hybridization was
carried out for 40 hours at 65°C in a rotating oven (Agi-
lent) at 20 r.p.m. The hybridization chambers were then
disassembled and array slides were washed for 5 minutes
at room temperature in Agilent Oligo aCGH Wash Buffers
1, followed by 1 minute at 37°C in Agilent Oligo aCGH
Wash Buffer 2 (p/n 5188-5226) (prewarmed to 37°C over-
n i g h t ) .T h es l i d e sw e r er e m o v e df r o mt h ew a s hb u f f e r2
slowly (5-10 seconds) after which time they were comple-
tely dry and were scanned using an Agilent DNA Microar-
ray scanner with 5 μm resolution. The data of microarray
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ware v9.5 in which a modified Feature Extraction protocol,
CGH-v4_95_Feb07 was used in conjunction with a gene
list on chromosome 21 q-arm to normalize spot-intensity
values and ratios to each extraction set. These ratio data
along with associated error values and flagged features
were imported into CGH Analytics Software v3.4 (Agi-
lent). The dye reversal data and intra-replicate spots were
then combined while the data centralization and fuzzy
zero algorithms were not applied in the CGH Analytics.
To make aberration calls, an aberration detection algo-
rithm, ADM-2 [14] was used at threshold 10 and an aber-
ration filter was set at 2 for the minimum number of
probe region and 1 for minimum absolute average log2
ratio for regions in the CGH Analytics to reduce false
positives.
Gene Expression Analysis
All RNA labeling reactions and hybridizations were carried
out following the manufacture’s protocol (Agilent One-
Color Microarray-Based Gene Expression Analysis, Ver-
sion 5.0.1). Briefly, polyA(+)RNA in 500 ng of total RNA
was primed with an oligo (d)T-T7 primer and converted
into dsDNA with MMLV-RT, then transcribed and simul-
taneously labeled with Cyanine 3-CTP for 2 hours at 40°C
using Agilent Low RNA Input Linear Amplification Kit
(p/n 5188-5339). After labeling and cRNA purification,
cRNA was quantified and the specific dye incorporation
activity was validated using the NanoDrop ND-1000. 1.65
μg of labeled cRNA was mixed with Agilent 10×Blocking
Agent and 25×Fragmentation Buffer, then incubated at
60°C for 30 hours. After fragmentation, the cRNA mix-
tures were immediately mixed with Agilent 2×Hybridiza-
tion Buffer (p/n 5188-5339) and applied to the Agilent
Human 4×44 K whole genome microarrays (G4112F) for
17 hours at 65°C (10 r.p.m.). Array slides were washed
with Agilent Gene Expression Wash Buffer 1 and 2 (p/n
5188-5327) and then scanned using the Agilent DNA
Microarray scanner with 5 μmr e s o l u t i o na n dt h e
eXtended Dynamic range setting (XDR Hi 100%, Low
10%) to avoid saturated features. The data of microarray
images were extracted by Agilent Feature Extraction Soft-
ware v9.5 using the GE1_v5_95 protocol. The extracted
signal intensities and flagged information were imported
into GeneSpring 7.3.1 software and the data sets were nor-
malized by adjusting the intensity distribution of well-
above background and unflagged features to 50th percen-
tile to account for the interchip variability. Comparison of
MCF7 and MCF7-ADR was done using duplicate array
data set for each cell line.
miRNA Expression Analysis
All RNA labeling reactions and hybridizations were car-
ried out following the manufacture’s prototype protocol
(Agilent miRNA Microarray system, Version 0.3, early
access). Briefly, 100 ng of total RNA including fraction of
small mature miRNA was dephosphorylated by calf intes-
tine alkaline phosphatase (p/n E2250Y, Amersham Bios-
ciences) for 30 minutes at 37°C and denatured by adding
DMSO (p/n D8418, Sigma) for 8 minutes at 100°C. Liga-
tion was then carried out with T4 RNA ligase (p/n
E2050Y, Amersham Biosciences) and pCp-Cy3 (p/n
5190-0408, Agilent) for 2 hours at 16°C that allowed us
to perform a quantitative direct labeling method [15].
The labeled miRNAs were desalted with Micro Bio-Spin
6 column (p/n 732-6221, Bio-Rad) and combined with
Agilent 10×GE Blocking Agent and 2×Hybridization Buf-
fer (p/n 5190-0408). The mixture was heated for 5 min-
utes at 100°C and immediately cooled to 0°C. Each
sample was hybridized to the Agilent early access Human
8×15 K microRNA microarrays covered 470 miRNAs
(AMADID 015508, early access) for 20 hours at 55°C
(20 r.p.m.). Array slides were washed with 6× SSC/
0.005% Triton X-100 for 10 minutes, then 0.1× SSC/
0.005% Triton X-100 for 5 minutes, both at room tem-
perature. Slides were scanned using the Agilent DNA
Microarray scanner with 5 μmr e s o l u t i o na n dt h e
eXtended Dynamic range setting (XDR Hi 100%, Low
5%) to avoid saturated features. The data were extracted
by Agilent Feature ExtractionS o f t w a r ev 9 . 5u s i n gt h e
miRNA_120106 protocol which extracts intensities of
multiple probes with multiple features per probe and
reports the measurements and errors as the TotalGen-
eSignal and TotalGeneSignalError for each of the miR-
NAs. These values were imported to the GeneSpring GX
version 7.3.1 without applying any normalization algo-
rithm. The miRNA profiles generated on the Agilent
platform were prior normalized to the amount of input
total RNA in which 100 ng of total RNA were equally
used for each assay and all of the labeled targets were
loaded on each array. Comparison of MCF7 and MCF7-
ADR was done using duplicate array data set for each cell
line.
Transfection of miRNA into MCF7-ADR-Luc cells
For MCF7-ADR-Luc cells, transfection of miRNA was car-
ried out using DharmaFECT 1 (Dharmacon) according to
the manufacturer’s protocol. MCF7-ADR-Luc cells were
plated in growth medium 24 hours before transfection.
The cells, which were grown to 50% confluence, were
transfected with 20 nM miRNAs and cultured. Two or
3 days after transfection, the cells were subjected to
further analyses.
Apoptosis assay measurement of caspase activity in vitro
Caspase-7, which plays key effecter roles in apoptosis,
was detected in caspase-3-deficient MCF7-ADR-Luc
cells. The arrays used in an in vitro growth assay were
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7 Assay (Promega) according to the manufacturer’s
instructions. Cells were incubated with the Apo-ONE
Caspase-3/7 Assay Reagent for 1.5 hours at room tem-
perature, and the fluorescence was then measured at
485Ex/535Em with a Wallac Multi-label Counter.
Hoechst staining
Cells were washed with PBS(-), and a fixative and staining
solution was added (4% paraformaldehyde, 1 μg/ml
Hoechst 33342 in PBS). Ten minutes after incubation,
cells were washed with PBS, and the number of apoptotic
cells was then determined in three microscopic fields of
each well by fluorescence microscopy (Olympus).
Luciferase assay for the measurement of cell growth
MCF7-ADR-Luc cells were plated into 5 × 10
3 cells per
well and cultured. The cell growth in each well was then
estimated by firefly luciferase activity because the cell
numbers were correlated with the bioluminescence from
MCF7-ADR-Luc cells. Luciferase assays were performed
with a Wallac Multi-label Counter (PerkinElmer) and
Bright-Glo Luciferase Assay System (Promega, Tokyo,
Japan) according to the manufacturer’s protocol.
Real-time RT-PCR
The total RNA was used to produce cDNAs with the
SuperScript™ II First-Strand Synthesis System (Invitrogen,
Tokyo, Japan) according to the manufacturer’sp r o t o c o l .
For quantification, cDNA samples were subjected to real-
time PCR using Platinum SYBR Green qPCR SuperMix
UDG (Invitrogen) in triplicates, and reactions were carried
out in an ABI PRISM 7300 (Applied Biosystems, Tokyo,
Japan). The specific sequences of primers for the analyzed
genes are shown in Additional File 1 Table S1. The
expression levels of genes were normalized to GAPDH.
For miRNA real-time RT-PCR, total RNAs of approxi-
mately 100 ng were reverse-transcribed using the Taqman
miRNA reverse transcription kit (Applied Biosystems).
Real-time quantitative PCR amplification of the cDNA
template was done using Taqman Universal PCR Master
Mix (Applied Biosystems, Tokyo, Japan) in an ABI PRISM
7300 (Applied Biosystems). The PCR conditions were
50°C for 2 minutes and 95°C for 10 minutes followed by
50 cycles of 95°C for 15 seconds and 60°C for 1 minute.
Taqman probes for human were used to assess the expres-
sion levels of miRNAs (hsa-miR-505, ID: 4373230, hsa-
miR-130, ID: 000454, and hsa-miR-155, ID: 002623).
3’UTR assay plasmid constructs
A 1235 bp fragment from the 3’U T Ro fA k t 3c o n t a i n i n g
the predicted target sequence of miR-505 (located at posi-
tions 529-535 of the Akt3 3’UTR) and a 934 bp fragment
from the 3’UTR of Akt3 containing the predicted target
sequence of miR-505 (located at positions 529-535 of this
fragment) were PCR-cloned from MCF7-ADR cells iso-
lated total RNA. Three prime A-overhang was added to
the PCR products after 15 minutes of regular Taq poly-
merase treatment at 72°C. The PCR products were cloned
into a pGEM-T easy vector (Promega). The amplified pro-
ducts were ligated into the NotI sites of the 3’UTR of the
Renilla luciferase gene in the psi-check-2 plasmid (Pro-
mega) to generate psi-Akt3_1 (1235 bp) and psi-Akt3_2
(934 bp). Primer sequences used for PCR-cloning were
shown as below: Akt3_F, GAGCCAGAGAGCATCT
TTCC, Akt3_R1, GCTGCCTTAGTAAAATGCCC, and
Akt3_R2, GACTTCACAGGCTGCTTTGG.
Statistical analysis
The results are given as the mean ± s.d. Statistical analy-
sis was conducted using the analysis of variance with the
Student’s t-test. A P value of 0.05 or less was considered
to indicate a significant difference.
Results
An integrated genomic analysis unveils the status of
cancer cells
MCF7-ADR is a multi-drug resistant cell line derived
from MCF7 breast cancer cell line. We utilized these two
cell lines to understand the regulatory network underly-
ing drug resistance in breast cancer and conducted three
types of genomic analysis, i.e. array-based comparative
hybridization (aCGH) (Figure 1B), miRNA (Additional
File 2 Figure. S1A) and gene expression (Additional File
2 Figure. S1B). Genes and miRNAs, which are located on
the genome-amplified and -deleted regions, are expected
to be responsible for drug resistance and sensitivity.
Moreover, these three types of array data were used for
miRNA target prediction and pathway to further eluci-
date key factors for drug resistance (Figure 1A).
As a consequence of array-based CGH, changes in DNA
copy number in MCF7-ADR and MCF7 as compared with
normal female genome were found in a large number of
regions as amplification and deletion (Figure 1B). Accuracy
of array-based CGH was validated by dye flip experiment
that exhibited strikingly mirroring images (Additional File
3 Figure. S2). The numbers of genes and miRNAs located
on the amplified and deleted genome regions (fold change
> 3) in MCF7-ADR and MCF7 cells are shown (Figure
1C). On further comparison, a large number of changes in
gene and miRNA expressions were observed between
MCF7 and MCF7-ADR (Additional File 2 Figure. S1A and
B). These genes with aberrant differences were observed
predominantly in amplified region in MCF7 and, in con-
trast, they were mainly in deleted regions in MCF7-ADR
(Figure 1B and 1C). In a different criterion of aCGH data
(fold change > 2), we could see the same propensity more
clearly (Additional File 4 Figure. S3A and B).
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Page 4 of 16Figure 1 An integrated genomic analysis to clarify drug resistance in MCF7-ADR (drug-resistant breast cancer cell line). (A) Schematic
representation of an integrated genomic analysis. During the acquisition of drug resistance in breast cancer cell (MCF7; parental cell line and
MCF7-ADR; drug resistance cell line), a large number of genomic alterations were raised, such as amplification or deletion, to modulate the
expression of genes and miRNAs. Based on aCGH, miRNAs and genes on the aberration region of genome are selected for further analysis of its
target genes and their associated-pathways in silico. (B) aCGH analysis of MCF7 and MCF7-ADR as compared with normal human female
genome. Blue line shows normal vs. MCF7, and red line shows normal vs. MCF7-ADR (top). Amplified or deleted genome regions (fold change >
3) are highlighted (bottom). (C) The numbers of genes and miRNAs located on the amplified or deleted genome regions (FC > 3). (D and E) The
expression tendency of genes located on the aberrant genome regions. 426 genes from MCF7 amplified regions and 6 genes from MCF7-ADR
amplified regions are plotted in left panels of each scatter plot. Six genes from MCF7 deleted regions and 25 genes from MCF7-ADR deleted
regions are plotted in right panels of each scatter plot.
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thought to be associated with up- and down-regulation
in expression, respectively, 426 genes on the amplified
region in MCF7 and 6 genes on the deleted regions in
MCF7 were plotted (Figure 1D). When the expression
levels of amplified 426 genes and deleted 6 genes were
checked, the expression of 426 genes tended to increase
(Figure 1D left), and vice versa that of 6 genes tended to
decrease in MCF7 as compared with MCF7-ADR (Fig-
u r e1 Dr i g h t ) ,a l t h o u g ht h e s eg e n en u m b e r sw e r e
counted based on the comparison of MCF7 and normal
female genome. Consistent with MCF7 result, we can
see similar tendency in gene expression in the result of
MCF7-ADR (Figure 1E), indicating that the gene expres-
sion levels and genomic alterations are broadly corre-
lated in this experiment.
An integrated genomic analysis reflects the unique
features of drug resistance in breast cancer cells
We hypothesized that genes and miRNAs in the region of
genomic alteration were relevant to drug resistance in
MCF7-ADR cells. In the most amplified region in MCF7-
ADR, we found MDR1 gene, which is an important efflux
pump for drug resistance. Its genome locus was amplified
more than 20-fold (Figure 2A), and its expression was up-
regulated 800-fold or more in MCF7-ADR by microarray
(Figure 2B). Expression level of MDR1 was confirmed by
real-time RT-PCR and was observed to be remarkably up-
regulated in MCF7-ADR consistent with our previous
study (Figure 2C) [13], suggesting that the genomic ampli-
fication and overexpression of MDR1 were one of the rea-
sons for drug resistance of MCF7-ADR.
Next, we tried to know the target genes of differentially-
expressed miRNA in MCF7-ADR, because these genes
might act as key molecules for drug resistance. Seventy-
four miRNAs were 2 fold or more up-regulated in MCF7-
ADR (Figure 3A), and we selected genes that have binding
sites of more than 15% of up-regulated miRNAs in their
3’UTR. The scatter plot shows expression levels of these
genes (Figure 2D), and 3 gene names are displayed
because their expression levels are considerably down-
regulated in MCF7-ADR. One of them is tumor protein
p53 inducible nuclear protein 1 (TP53INP1) (Figure 2D),
which has been recently shown to be suppressed by several
miRNAs such as miR-130 and miR-155 [16,17]. Further-
more, decreased expression of TP53INP1 is involved in
breast cancer progression [18]. As shown in Figure 2E,
expression of miRNAs which potentially bind to 3’UTR of
TP53INP1 were plotted, and it displays names of miRNAs
whose expression levels were considerably up-regulated in
MCF7-ADR. These included miR-130 and miR-155 also
known as TP53INP1 binding miRNAs, and most of them
are highly expressed in MCF7-ADR, indicating that these
miRNAs and TP53INP1 expressions were inversely
correlated. From the real-time RT-PCR analysis, down-
regulation of TP53INP1 and up-regulation of miR-130
a n dm i R - 1 5 5i nM C F 7 - A D Ra sc o m p a r e dw i t hM C F - 7
(Figure 2F and 2G). Taken together with our results and
recent publications, our integrated genomic analysis can
clearly reflect the status of multi-drug resistant MCF7-
ADR.
Pathway analysis of up- and down-regulated miRNA
target genes
Cancer cells abrogate the function of drug sensitive genes,
such as tumor suppressor gene and related-gene pathway
after the anticancer drug treatment, and thus we specu-
lated that differentially-expressed miRNAs between
MCF7-ADR and MCF7 controlled the gene pathway gov-
erning drug resistance. As shown in Figure 3A, 74 miR-
NAs and 32 miRNAs were up- and down-regulated in
MCF7-ADR, respectively. Target gene prediction showed
up-regulated 74 miRNAs had 5, 137 genes and down-
regulated 32 miRNAs had 3, 579 genes as target candi-
dates (Figure 3A). Expression levels of these genes were
plotted in the scatter plots, however, decreasing and
increasing expression tendencies were not clearly observed
(data not shown). So, with these genes, we next checked
what kind of gene pathways were expected to be regulated
by differentially-expressedm i R N A s .Al a r g en u m b e ro f
pathways were significantly chosen (Top 20 pathways
shown in Additional File 5 Table S2). Surprisingly, many
common pathways were enriched in both up-and down-
regulated miRNA targeted genes, suggesting that the dif-
ferentially-expressed miRNAs orchestrated to lead the glo-
bal gene expression changes in MCF7-ADR. Intriguingly,
these miRNAs seem to regulate some of drug resistance
related signaling pathways, such as Wnt, insulin, EGFR1,
MAPK and TGF-beta receptor (Additional File 5 Table
S2, Figure. 3B and Additional File 6 Figure. S4). This data
shows the possibility that differentially-expressed miRNAs
might cooperatively regulate their target pathways and
change drug resistance and sensitivity in MCF7-ADR.
Identification of miRNAs that suppress cell proliferation in
MCF7-ADR
We next explored whether the miRNAs that were located
on the aberrant genome regions played a role in regulating
drug resistance of MCF7-ADR. To this end, genomic sta-
tus between MCF7-ADR and MCF7 were directly com-
pared (Figure 4A). The numbers of genes and miRNAs
that were located on the aberrant regions are shown (Fig-
ure 4B) and most of them were on the deleted regions in
MCF7-ADR. A scatter plot showed 49 miRNAs on the
deleted genomic regions in MCF7-ADR (Figure 4C) and
expression levels of these 49 miRNAs had decreasing
trend in MCF7-ADR. In this study, we focus on miRNAs
whose expressions were down-regulated and genomic
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Page 6 of 16Figure 2 Genomic amplification and overexpression of MDR1, and a number of miRNA regulation of TP53INP1.( A )T w e n t yf o l d
amplification of multi-drug resistance gene (MDR1) region in MCF7-ADR as compared with MCF7. (B and C) Overepression of MDR1 gene in
MCF7-ADR by microarray and real-time PCR, respectively. (D) Scatter plot of miRNA target genes predicted by Targetscan. More than 15% of
miRNAs up-regulated in MCF7-ADR (74 miRNAs) were predicted to potentially bind the 3’-UTR of these genes. Expression levels of three
(TP53INP1, PURB and TRPS1) of them are clearly dwon-regulated. (E) Scatter plot of miRNAs that might bind to 3’UTR of TP53INP1 gene. (F and
G) Confirmation of TP53INP1 gene, miR-130 and miR155 expression by real-time PCR. Standard deviation was calculated in triplicate
determinants in the experiment.
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Page 7 of 16Figure 3 Pathway enrichment analysis of up- and down-regulated miRNAs in breast cancer cells. (A) Diagram of GO analysis of MCF7 and
MCF7-ADR. In the comparison with MCF7 and MCF7-ADR, 5, 137 genes and 3, 579 genes are predicted as miRNA target candidates of 74 up-
regulated miRNAs and 32 down-regulated miRNAs, respectively. With these predicted genes, enriched pathways are selected, as shown Table S1.
(B) Wnt signaling pathway. 74 miRNA-targeted genes are plotted in Wnt signal pathway map (left), 32 miRNA-targeted genes are plotted (right).
Red boxes show high expression genes, and green boxes show low expression genes.
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Page 8 of 16Figure 4 Screening of miRNAs responsible for drug resistance in MCF7-ADR. (A) Direct comparison of MCF7 and MCF7-ADR genomic
status based aCGH. Modified Figure1B, differences in genomic status between MCF7 and MCF7-ADR are shown (FC > 2). (B) The number of
genes and miRNAs located on the amplified or deleted genome regions in MCF7-ADR as compared with MCF7 (FC > 2). (C) Scatter plot of 49
miRNAs that locates in the deleted genomic regions in MCF7-ADR. (D) Scatter plot of 72 miRNAs whose expression was down-regulated in
MCF7-ADR when compared with MCF7. (E) Twelve miRNAs (miR-23b, miR-25, miR-27b, miR-93, miR-106b, miR-189, miR-489, miR-505, miR-542-5p,
miR-565, miR-652 and let-7d), which are overlapped between deleted and down-regulated in MCF7-ADR, are candidates responsible for drug
resistance in MCF7-ADR. (F) Transfection analysis of selected 12 miRNAs in MCF7-ADR-Luc, which stably express luciferase. All miRNAs were
transfected at 20 nM. Seventy-two hours after transfection, cell growth was estimated by luciferase activity in MCF7-ADR-Luc cells (n = 3-6 per
group). P < 0.05.
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Page 9 of 16status was deleted in MCF7-ADR cells as compared to
MCF7. Expression levels of 72 miRNAs were significantly
down-regulated (p < 0.05, Additional File 7 Table S3 and
Figure 4D) and 49 miRNAs (Additional File 8 Table S4
and Figure 4C) were located in deleted regions (FC > 2) in
MCF7-ADR cells. Twelve miRNAs were overlapped
between the 72 down-regulated miRNAs and 49 deleted
miRNAs (Table 1 and Figure 4E).
To examine the functions of these miRNAs, we tested the
effects of 12 miRNAs on cell proliferation in MCF7-ADR
cells. The 12 miRNAs (miR-23b, miR-25, miR-27b, miR-
93, miR-106b, miR-189, miR-489, miR-505, miR-542-5p,
miR-565, miR-652, and let-7d) were transfected into
MCF7-ADR-Luc cells (Figure 4F). Interestingly, miR-25,
miR-93, and miR-106b are known as polycistronic miR-
NAs [19] and their expression and genomic region were
coincidently changed between MCF7-ADR and MCF7
(Additional File 9 Figure. S5). Consistent with previous
report, transfection with miR-93 and miR-106b promoted
cell proliferation as compared with negative control
miRNA, suggesting that they actually act as oncogenic
miRNAs [19,20]. Inversely, transfection of miR-505 and
let-7d inhibited the cell proliferation of MCF7-ADR-Luc
cells. Let-7 family is a well known tumor suppressive
miRNA as described in many reports [21-23]. Inhibitory
effects of cell growth by miR-505 and let-7d transfection
are at similar level (Figure 4F). These data suggest that
miR-505 is a novel tumor suppressive miRNA and plays a
role in the regulation of cell proliferation similar to let-7d.
miR-505 inhibits cell growth by inducing apoptotic cell
death in MCF7-ADR cells
Since transfection of miR-505 showed the inhibition of
cell proliferation effectively and significantly (Figure 4F
and 5A), we focused on miR-505 to evaluate its molecu-
lar function in this study. From the aCGH data, geno-
mic region of miR-505 locus in MCF7-ADR was deleted
(Figure 5B), in contrast it was intact in MCF7. The
expression level of miR-505 was also decreased by real-
time RT-PCR analysis in MCF7 and MCF7-ADR cells
(Figure 5C). To further examine the mechanism of cell
growth inhibition, we sought to check whether miR-505
is responsible for cell apoptosis in MCF7-ADR cells. A
mature form of miR-505 was transfected into MCF7-
ADR cells in the presence or absence of DOC (1 nM),
as MCF7-ADR cells are resistant to DOC, and caspase-7
activity was measured to estimate apoptotic cell death in
MCF7-ADR. The results of the caspase-7 assay indicated
that transfection of miR-505 with DOC resulted in a
marked induction of apoptosis (p < 0.05, Figure 5D),
although no significant difference was seen in the sam-
ples without DOC. We validated this result by counting
the Hoechst-stained cells showing apoptotic nuclear
condensation and fragmentation and found that signifi-
cantly higher apoptotic cell death was observed in cells
with miR-505 than in control miRNA (p <0 . 0 5 ,F i g u r e
5E and 5F). Taken together, we concluded that transfec-
tion of miR-505 inhibit the growth of drug resistance
cells, MCF7-ADR, through the inducing apoptosis.
Akt3, correlates inversely with miR-505 expression,
modulates drug sensitivity
It has been already known that drug resistance in cancer
cells was an acquired characteristic by activation of multi-
ple drug resistance-responsible genes. To investigate what
kind of the genes are responsible for the drug sensivity by
m i R - 5 0 5i n d u c eg e n es u p p r e s s i o n ,w ec o m b i n e dg e n e
expression data and gene ontology (Figure 6A). As for
gene expression data, since the expression level of
miRNA-regulating genes was up-regulated when miRNA
expression was lower in MCF7-ADR than in MCF7 cells,
up-regulated genes judged by the T-test (1, 758 genes,
Additional File 10 Table S5) were selected as candidates of
miR-505. As miR-505-targeted genes, apoptosis-related
genes (153 genes, Additional File 11 Table S6) were cho-
sen using a database (KEGG web site, http://www.genome.
Table 1 Selected 12 miRNAs
Name MCF7-ADR/MCF7 Chromosome Start Stop
hsa-miR-565 0.48 3 45705468 45705564
hsa-miR-489 0.01 7 92951184 92951267
hsa-miR-25 0.16 7 99529119 99529202
hsa-miR-93 0.15 7 99529327 99529406
hsa-miR-106b 0.15 7 99529552 99529633
hsa-let-7d 0.37 9 95980937 95981023
hsa-miR-23b 0.18 9 96887311 96887407
hsa-miR-27b 0.12 9 96887548 96887644
hsa-miR-189 (miR-24) 0.00 9 96888124 96888191
hsa-miR-652 0.18 X 109185213 109185310
hsa-miR-542-5p 0.56 X 133501037 133505133
hsa-miR-505 0.53 X 138833973 138834056
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Page 10 of 16Figure 5 miR-505 inhibits cell growth by inducing apoptotic cell death in MCF7-ADR. (A) Images show typical MCF7-ADR cells transfected
with miR-505 (top) and control miRNA (bottom) in 72 hours. (B) DNA copy number on the miR-505 locus of MCF7-ADR deleted as compared
with that of MCF7. (C) Real-time RT-PCR analysis was performed to determine expression levels of miR-505 in parental cell line MCF7 and drug-
resistant cell line MCF7-ADR. Error bar represents S.D. of triplicate determinations in a single experiment. P < 0.05. (D). Seventy-two hours after
transfection, caspase-7 activity in the presence or absence of DOC (1 nM) was detected in miR-505 or control miRNA-transfected MCF7-ADR
cells. n = 6, P < 0.001. (E) Condensed and fragmented apoptotic cells are counted in the presence or absence of DOC (1 nM) by staining with
Hoechst dye. n = 4, P < 0.05. Mean ± S.D. is shown. (F) Images of apoptotic nuclear condensation and fragmentation. Seventy-two hours after
transfection with miR-505 (top) or control miRNA (bottom), condensed and fragmented cells are observed. White arrows show apoptotic cells in
culture.
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Page 11 of 16Figure 6 Akt3, whose expression was inversely correlated with miR-505, is associated with drug resistance in MCF7-ADR cells.( A )
Scatter plot of 2 probes of Akt3 genes that up-regulated in MCF7-ADR cells. (B) Real-time RT-PCR analysis for Akt3 in miR-505 or control miRNA-
transfected cells. Seventy-two hours after transfection with miR-505 or control miRNA, Akt3 expression levels were determined. Expression levels
were normalized to GAPDH expression levels. N = 9, mean ± S.D. is shown. (C) Down-regulation of Akt3 induced cell growth arrest in MCF7-ADR
cells at 1, 10 and 20 nM DOC conditions. Cell growth was calculated by luciferase activity. n = 3, *, P < 0.05. **, 0.01.
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Page 12 of 16jp/kegg/) because transfection of miR-505 induced apopto-
tic cell death in MCF7-ADR-Luc cells. By combining these
data, we postulated that Akt3 gene is candidate of miR-
505-regulating gene, which is responsible for the drug
resistance in breast cancer cell (Figure 6A). Notably, sev-
eral studies have reported that Akt3 promotes melanoma
development [24] and that the down-regulation of Akt3
distinctly inhibited the proliferation of ovarian cancer cell
lines by slowing G2-M phase transition [25]. Given this
evidence and the observed phenotype in miR-505-trans-
fected MCF7-ADR-Luc cells, we sought to determine
whether Akt3 was a target of miR-505 or not. As shown in
Figure 6B, decrease in relative gene expression was
observed with miR-505 in MCF7-ADR-Luc cells, suggest-
ing that miR-505 suppresses the gene expression of Akt3.
However, we found that miR-505 could not bind to the 3’-
UTR of Akt3 gene (Additional File 12 Figure. S6), indicat-
ing that down-regulation of Akt3 after miR-505 overex-
pression was caused by indirect effect of miR-505-
mediated gene suppression. Finally, transfection of Akt3
siRNA was conducted to examine whether down-regula-
tion of the Akt3 gene induced cell growth arrest in the
presence or absence of DOC. Three days after transfec-
tion, the expression of Akt3 was clearly suppressed (Addi-
tional File 13 Figure. S7), and cell growth rates were
assayed with or without 1, 10, and 20 nM DOC condi-
tions. A slight decrease in cell growth was observed with
1 nM DOC condition, and more remarkable decreases
was detected with 10 and 20 nM DOC conditions in Akt3
siRNA-transfected MCF7-ADR cells than in control
siRNA-transfected cells (Figure 6C). Therefore, our data
show that Akt3, whose expression is correlated conversely
with miR-505, regulates DOC sensitivity in MCF7-ADR
cells.
Discussion
According to recent high-throughput analyses of both
coding and non-coding genes, cancer progression is
caused by genetic alteration involving structural and
expression abnormalities of oncogenes and tumor sup-
pressor genes [6,26]. In this study, we performed an inte-
grated genomic analysis to link miRNA expression data
to aCGH and gene expression microarray, using the par-
ental cell line MCF7 and the drug-resistant cell line
MCF7-ADR, to examine the molecular mechanism gov-
erning drug resistance in breast cancer. We found that
the expression of miR-505 was down-regulated, and its
genomic region was deleted in MCF7-ADR cells, which
provided evidence that miR-505 was a tumor suppressive
miRNA and had a pivotal role for inducing apoptosis in
drug resistant cancer cells. In addition, by using the data
of gene expression and bioinformatics analysis (gene
function), our data identified Akt3 whose expression was
conversely correlated with miR-505, which modulated
drug sensitivity in MCF7-ADR.
Akt is a homolog of the retroviral oncogene v-Akt,
which is ubiquitously expressed and has 3 members;
Akt1, Akt2, and Akt3 [27]. Downstream genes of the Akt
signal pathway modulate the cell cycle, DNA repair, and
nitric oxide production. Moreover, Akt inhibits apoptotic
cell death by inactivation of a key apoptotic molecule and
is broadly activated in various kinds of cancer. Impor-
tantly, the Akt signal pathway is tightly related to drug
resistance in cancer. Several studies have reported that
inactivation of Akt promotes drug-induced apoptosis
[28,29]. Therefore, inhibition of Akt3 is a therapeutic
strategy for cancers by inducing apoptotic cell death and
reversing drug resistance. However, our results showed
that inhibition of Akt3 was less effective than transfection
of miR-505 in cell growth arrest. A simple explanation of
a low effect might be that miRNA could modulate the
expression of a large number of downstream target genes
in a highly orchestrated manner to control apoptosis and
cell cycle processes
Concerning the variations in the DNA copy numbers
and genomic aberrations, several reports have shown
the deletions of miRNAs that act as tumor suppressors,
namely miR-15, miR-16, and miR-34a. They are
observed in cancer, and down-regulation of these miR-
NAs contributed to cancer progression, indicating that
variations in DNA copy numbers are closely associated
with miRNA expression and carcinogenesis [9,10].
Meanwhile, several data provided evidences that miRNA
expressions were regulated by epigenetic modifications,
such as DNA hypomethylation and hypermethylation. It
has been demonstrated that miR-342 was methylated in
colorectal cancer and the reconstitution of miR-342
induced apoptosis in a colorectal cancer cell line [30]. A
recent study showed that miR-127, which was embedded
in a CpG island, was expressed in normal fibroblast but
silenced or down-regulated in cancer cells. The silencing
of the miRNA promoter region of miR-127 was
mediated by CpG island hypermethylation, which could
be reversed by simultaneous treatment with the chroma-
tin-modifying drugs 5-aza-2’-deoxycytidine and 4-phe-
nylbutyric acid [31]. In addition, recent studies have
shown that impaired miRNA processing contributes to a
decrease in mature miRNA expression and accelerates
tumorigenesis [32], and a number of groups have also
revealed that miRNA expression is regulated by tran-
scription factors and cytokines as well as coding genes
[33]. In this study, we found 12 miRNAs whose expres-
sions are down-regulated and their genomic regions are
deleted in MCF7-ADR. Interestingly, some of them,
such as miR25-93-106b and miR-23b-27b-189, are
located in close proximity and their expressions are
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regulators. Curiously, miR-23b-27b-189 is localized on
the Ch9q22.3, and LOH of this region is strongly corre-
lated with cancer progression and lymph node metasta-
sis [34-36]. In our assay we could not observe any
significant differences, however, they could be related to
malignancy in different aspects [37,38].
Pathway analysis, which was based on miRNA target
prediction, proved that differentially-expressed miRNA
cooperatively regulated a large number of signaling path-
ways, including Wnt, insulin, EGFR1, MAPK and TGF-b
receptor, which are relevant to drug resistance as well as
tumorigenesis. Concerning the Wnt signaling pathway, it
has been reported that activation of the Wnt/b-catenin
pathway plays critical roles in establishment of MLL leu-
kemic stem cells and conferring drug-resistant properties
[39]. Additionally, activation of Wnt/beta-catenin signal-
ing in plasma cells induced chemoresistance [40], and
RNAi-mediated gene silencing of b-catenin negatively
regulated drug-induced apoptosis [41]. Therefore, Wnt/
b-catenin signaling pathway would be a potential thera-
peutic target to sensitize drug-resistant cancer cell.
Furthermore, other pathways were also reported to be
associated with drug resistance and apoptosis. Sequential
treatment of TGF-b induced MDR1 expression in rat
hepatocytes [42]. In contrast, TGF-b also induces apopto-
tic cell death in hepatocytes and activation of the MAPK/
ERK pathway confers resistance to TGF-b-induced cell
death [43]. Our findings showed that a lot of pathways
were commonly enriched in up- and down-regulated
miRNA targets, however, it is hard to decide whether
these pathways are positively or negatively regulated in
MCF7-ADR, because a large number of target candidates
exist in each signaling pathway. Further investigation
such as systems biology would be needed to clarify this
point.
We believe that the integrative genomic analyses as
described here have a huge potential to fundamentally
understand transcriptional regulatory networks and iden-
tify the novel molecular targets for therapy in the field of
cancer biology. By integrating array data and bioinfor-
matics, it could be possible to expeditiously explore the
key molecule in the all aspects of pathophysiology. Our
studies by means of an integrated genomic analysis not
only identified miR-505 as a tumor suppressive miRNA
that inhibited cell proliferation by inducing apoptotic cell
death but also, more broadly highlighted that various
genes and miRNAs orchestrate to temper the drug resis-
tance by intricately controlling genomic status, gene and
miRNA expression in cancer cells. Thus, it would be a
useful approach to accelerate the understanding of cancer
genetics and discover the key targets for diagnosis, prog-
nosis and therapy.
Additional material
Additional file 1: Table S1. Primer list for real-time PCR.
Additional file 2: Figure. S1. Microarray analysis of gene expression and
miRNA in MCF7-ADR and MCF7. (A) Scatter plot of gene expression. 41,
000 probes (n = 3). (B) Scatter plot of miRNA expression. 470 probes (n =
2).
Additional file 3: Figure. S2. Validation of accuracy of aCGH in MCF7
and MCF7-ADR. (A) aCGH analysis of MCF7. (B) aCGH analysis of MCF7-
ADR. For each sample, the experiment was repeated once, wherein the
dye was reversed between the experimental and the reference sample,
in order to account for dye-incorporation bias. An aberration filter was
set at 2 for the minimum number of probe region and 1 for minimum
absolute average log2 ratio for regions in the CGH Analytics to reduce
false positives.
Additional file 4: Figure. S3. aCGH analysis of MCF7 and MCF7-ADR as
compared with normal human female genome. (A) Blue line shows
normal vs. MCF7, and red line shows normal vs. MCF7-ADR (top).
Amplified or deleted genome regions (fold change > 2) are highlighted
(bottom). (B) The numbers of genes and miRNAs located on the
amplified or deleted genome regions (FC > 2).
Additional file 5: Table S2. Up and Down miRNA target gene related
pathways.
Additional file 6: Figure. S4. TGF-b signaling pathway. Seventy-four
miRNA-targeted genes are plotted in TGF-b signaling pathway map (left),
32 miRNA-targeted genes are plotted (right).
Additional file 7: Table S3. List of down-regulated miRNAs in MCF7-
ADR.
Additional file 8: Table S4. List of miRNAs located in genome deletion
regions in MCF7-ADR.
Additional file 9: Figure. S5. Polycistronic miRNAs; miR-106-25 cluster.
miR-106-25 cluster is located on the deleted genomic region, and the
expression is coincidently downregulated.
Additional file 10: Table S5. List of up-regulated genes in MCF7-ADR
judged by T-test in comparison with MCF7.
Additional file 11: Table S6. List of genes accosiated with apoptosis
(KEGG web site).
Additional file 12: Figure. S6. The 3’-UTR assay of Akt3 by miR-505 in
MCF7-ADR cells and HEK293 cells. (A) MCF7-ADR cells and (B) HEK293
cells were co-transfected with pre-miR-505 or pre-NC and the psi-Akt3_1
or with psi-Akt3_2. After 48 h, luciferase activities were measured. n.s.
represents not significant.
Additional file 13: Figure. S7. Real-time RT-PCR analysis of Akt3 gene
by transfection of siRNA in MCF7-ADR cells. Real-time RT-PCR analysis
was performed to examine Akt3 from RNA extracted from MCF7-ADR
cells transfected with either Akt3 siRNA or negative control siRNA. Akt3
expression levels were normalized to GAPDH expression levels. The mean
± S. D. of results from triplicate transfections is shown. Results represent
the mean ± S. D. (n = 3). Since Akt3 siRNA-1 was most effectively
inhibited the expression of Akt3 genes, it was used for the analysis of
cell growth arrest.
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